Overview

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Status:
Not yet recruiting
Trial end date:
2023-08-10
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
Phase:
Phase 1
Details
Lead Sponsor:
CTI BioPharma
Collaborator:
PPD
Treatments:
Bosentan
Fluconazole